Cannabis Market in Germany

Germany represents the largest cannabis market in Europe and has been a focal point for international cannabis investment since legalizing medical cannabis in 2017. The German medical cannabis market has grown rapidly, driven by a relatively accessible prescription framework where any physician can prescribe cannabis for any condition when conventional treatments are inadequate. Insurance coverage through Germany's statutory health insurance system (Gesetzliche Krankenversicherung) further differentiates the market from most other countries, as patients can often receive cannabis with minimal out-of-pocket costs.

In April 2024, Germany took a historic step by partially legalizing recreational cannabis. The new law allows adults to possess up to 25 grams in public, grow up to three plants at home, and participate in nonprofit cannabis cultivation associations (Anbauvereinigungen). However, commercial sales through licensed retail shops — which would create the larger economic opportunity — are being tested through regional pilot programs rather than implemented nationwide immediately. This phased approach reflects the political compromise required to pass the legislation and means the full commercial recreational market will take years to develop.

The German medical cannabis market is supplied by both domestic producers and imports, primarily from Canada, Portugal, and the Netherlands. Canadian LPs including Tilray (through its Aphria Germany subsidiary), Aurora Cannabis, and Canopy Growth have established significant operations in Germany, including cultivation facilities and distribution networks. German domestic companies like Demecan and various pharmacy-focused distributors also play important roles. The EU Good Manufacturing Practice (EU-GMP) certification required for cannabis production creates a meaningful barrier to entry and quality standard.

For cannabis investors, Germany matters not just as a standalone market but as a potential catalyst for broader European legalization. As the EU's largest economy and most populous member state, Germany's policy moves carry significant influence across the continent. The success or failure of Germany's recreational pilot programs could accelerate or delay similar efforts in other European countries. The German market also offers exposure to the pharmaceutical-grade cannabis supply chain, which requires different capabilities than North American consumer cannabis markets.